Rhythm pharmaceuticals announces pivotal phase 3 transcend trial meets primary endpoint with -19.8% placebo-adjusted bmi reduction in patients (n=120) with acquired hypothalamic obesity

-- patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean bmi change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p

BMI Ratings Summary

BMI Quant Ranking